PetMed Express (PETS) Releases Quarterly Earnings Results
PetMed Express (NASDAQ:PETS) announced its quarterly earnings results on Monday. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.11, Bloomberg Earnings reports. PetMed Express had a net margin of 12.84% and a return on equity of 34.04%. The company had revenue of $60.10 million for the quarter, compared to the consensus estimate of $56.76 million. During the same quarter in the prior year, the firm earned $0.24 earnings per share. The company’s revenue for the quarter was up 13.6% compared to the same quarter last year.
PetMed Express (NASDAQ PETS) opened at $50.66 on Wednesday. The firm has a market cap of $991.27, a P/E ratio of 29.98, a PEG ratio of 2.83 and a beta of 1.12. PetMed Express has a 52-week low of $19.21 and a 52-week high of $57.80.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 16th. Stockholders of record on Monday, February 5th will be given a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.97%. The ex-dividend date of this dividend is Friday, February 2nd. This is a positive change from PetMed Express’s previous quarterly dividend of $0.20. PetMed Express’s payout ratio is currently 47.34%.
In other news, Director Gian Fulgoni sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $44.38, for a total value of $887,600.00. Following the completion of the transaction, the director now owns 55,900 shares of the company’s stock, valued at $2,480,842. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Menderes Akdag sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $51.00, for a total transaction of $1,530,000.00. Following the transaction, the chief executive officer now directly owns 490,000 shares of the company’s stock, valued at approximately $24,990,000. The disclosure for this sale can be found here. In the last three months, insiders sold 51,000 shares of company stock valued at $2,453,170. Company insiders own 4.00% of the company’s stock.
A number of hedge funds have recently modified their holdings of PETS. Schwab Charles Investment Management Inc. increased its position in PetMed Express by 20.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 84,764 shares of the company’s stock worth $3,442,000 after purchasing an additional 14,456 shares during the last quarter. Legal & General Group Plc increased its position in PetMed Express by 9.0% during the second quarter. Legal & General Group Plc now owns 36,258 shares of the company’s stock worth $1,472,000 after purchasing an additional 2,992 shares during the last quarter. Principal Financial Group Inc. increased its position in PetMed Express by 4.0% during the second quarter. Principal Financial Group Inc. now owns 173,219 shares of the company’s stock worth $7,033,000 after purchasing an additional 6,741 shares during the last quarter. Alliancebernstein L.P. acquired a new position in PetMed Express during the second quarter worth approximately $2,212,000. Finally, Teachers Advisors LLC increased its position in PetMed Express by 5.3% during the second quarter. Teachers Advisors LLC now owns 65,173 shares of the company’s stock worth $2,646,000 after purchasing an additional 3,289 shares during the last quarter. 99.24% of the stock is owned by hedge funds and other institutional investors.
About PetMed Express
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.